PHOTOFRIN Drug Patent Profile
✉ Email this page to a colleague
When do Photofrin patents expire, and when can generic versions of Photofrin launch?
Photofrin is a drug marketed by Pinnacle Biolgs and is included in one NDA.
The generic ingredient in PHOTOFRIN is porfimer sodium. One supplier is listed for this compound. Additional details are available on the porfimer sodium profile page.
Summary for PHOTOFRIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 26 |
| What excipients (inactive ingredients) are in PHOTOFRIN? | PHOTOFRIN excipients list |
| DailyMed Link: | PHOTOFRIN at DailyMed |
Recent Clinical Trials for PHOTOFRIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 1 |
| Taoyuan General Hospital | Early Phase 1 |
| Pinnacle Biologics Inc. | Phase 1/Phase 2 |
Pharmacology for PHOTOFRIN
| Drug Class | Photoactivated Radical Generator |
| Mechanism of Action | Photoabsorption |
| Physiological Effect | Photosensitizing Activity |
Anatomical Therapeutic Chemical (ATC) Classes for PHOTOFRIN
US Patents and Regulatory Information for PHOTOFRIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pinnacle Biolgs | PHOTOFRIN | porfimer sodium | INJECTABLE;INJECTION | 020451-001 | Dec 27, 1995 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PHOTOFRIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pinnacle Biolgs | PHOTOFRIN | porfimer sodium | INJECTABLE;INJECTION | 020451-001 | Dec 27, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Pinnacle Biolgs | PHOTOFRIN | porfimer sodium | INJECTABLE;INJECTION | 020451-001 | Dec 27, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Pinnacle Biolgs | PHOTOFRIN | porfimer sodium | INJECTABLE;INJECTION | 020451-001 | Dec 27, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Pinnacle Biolgs | PHOTOFRIN | porfimer sodium | INJECTABLE;INJECTION | 020451-001 | Dec 27, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for PHOTOFRIN
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Pinnacle Biologics B.V. | PhotoBarr | porfimer sodium | EMEA/H/C/000493 Photodynamic therapy (PDT) with PhotoBarr is indicated for: Ablation of high-grade dysplasia (HGD) in patients with Barrett's Oesophagus (BO) |
Withdrawn | no | no | no | 2004-03-25 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for PHOTOFRIN
See the table below for patents covering PHOTOFRIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Netherlands | 940021 | ⤷ Try a Trial | |
| Norway | 180742 | ⤷ Try a Trial | |
| Denmark | 172284 | ⤷ Try a Trial | |
| Denmark | 210185 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PHOTOFRIN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0050800 | 96C0028 | Belgium | ⤷ Try a Trial | PRODUCT NAME: PORFIMERE SODIQUE; NAT. REGISTRATION NO/DATE: NL 19150 19960409; FIRST REGISTRATION: NL - RVG 16652 19940411 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
